Načítá se...
HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (<it>cis</it>-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas
<p>Abstract</p> <p>Background</p> <p>Lymphomas frequently retain wild-type (wt) p53 function but overexpress HDM2, thereby compromising p53 activity. Therefore, lymphoma is a suitable model for studying the therapeutic value of disrupting the HDM2-p53 interaction by sma...
Uloženo v:
Hlavní autoři: | , , , , , |
---|---|
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
BMC
2012-09-01
|
Edice: | Journal of Hematology & Oncology |
Témata: | |
On-line přístup: | http://www.jhoonline.org/content/5/1/57 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|